This trial is conducted in Europe. The aim of this trial is to determine the effect of NNC 90-1170 (liraglutide) on glucose and hormonal profiles, fasting gluconeogenesis and insulin secretion in subjects with type 2 diabetes.

Inclusion Criteria:

• Type 2 diabetes mellitus
• Diet treated and/or subjects in monotherapy with max. 50 % of maximal dose of sulphonylurea (SU). In addition, subjects in treatment with metformin and/or repaglinide could be included
• Body Mass Index (BMI) maximum 35 kg/m^2
• Fasting plasma glucose 7-15 mmol/l, both inclusive

Exclusion Criteria:

• Impaired liver function
• Impaired renal function
• Anaemia
• Cardiac disease
• Uncontrolled treated/untreated hypertension
• Recurrent major hypoglycaemia as judged by the Investigator
• Known or suspected allergy to trial product or related products
• Females of child bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures
• Current treatment with thiazolidinediones or chronic daily use of insulin (more than 7 days) within three months in the absence of intercurrent illness
• Loss of more than 400 ml blood during the three months prior to study start
• Allergy to paracetamol